

# Human VEGF-A Monoclonal Antibody

Catalog No.: YR0135

## Basic Information

### Molecular Weight

150 kDa

### Endotoxin

<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay

### Sterility

0.2 μm filtration

### Aggregation

<5% Determined by SECP

### Purity

>95% Determined by SDS-PAGE

## Background

Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.

## Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

## Immunogen Information

### Clone

Brolucizumab Biosimilar

### Isotype

Human IgG1 kappa

### Immunogen

Human VEGF-A

### Recommended Isotype Control(s)

In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

### Recommended Dilution Buffer

1×PBS pH 7.4

## Contact

☎ | 400-999-6126

✉ | [cn.market@abclonal.com.cn](mailto:cn.market@abclonal.com.cn)

🌐 | [www.abclonal.com.cn](http://www.abclonal.com.cn)

## Product Information

### Production

Purified from cell culture supernatant in an animal-free facility

### Purification

Protein A or G purification

### Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)